Additional genetic testing to screen for variants not covered by our short-read NGS approaches was performed in 81 patients with the majority accounting for C9orf72 repeat testing, which was negative in all 56 tested patients with a suspected MND. This evidence concerns the gene C9orf72 and mild neurocognitive disorder.